The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.
Is NETTER-2 a practice-changing trial?
Cives, Mauro
2024-01-01
Abstract
The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
NETTER 2 Nature_Reviews_Clinical_Oncology.pdf
non disponibili
Descrizione: Note
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright dell'editore
Dimensione
742.54 kB
Formato
Adobe PDF
|
742.54 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
